Evidence map›Paper›PMID 41510395›Full record

ArticleTranslational lung cancer research2025

Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with

Kuofang Huang, Zhihuang Hu, Shifei Pan, Jialin Qian, Xianghua Wu, Huijie Wang, Kai Wang, Haijiao Lu, Huishu Dong, Tianqing Chu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kuofang Huang *Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhihuang Hu *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shifei PanDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jialin QianDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xianghua WuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Huijie WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Kai WangShanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Haijiao LuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huishu DongDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tianqing ChuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jialei WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Real-world data on the application of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 ( Methods: This retrospective study was conducted at two centers in China. Clinical data were reviewed in patients who received T-DXd treatment. The primary outcomes were progression-free survival (PFS) and objective response rate (ORR). Results: Between April 2023 and January 2025, 35 patients were included. All patients had stage IV lung adenocarcinoma. Median age was 58 years (range, 33-87 years), and 18 (51.4%) patients were female. All patients received T-DXd as second- or further-line treatment. Most patients [24 (68.6%)] had Conclusions: This study firstly supplements real-world evidence on T-DXd treatment in Chinese patients with previously treated

Indexed as

human epidermal growth factor receptor 2 (HER2)non-small cell lung cancer (NSCLC)retrospective studyTrastuzumab deruxtecan (T-DXd)

Identifiers

PMID41510395
PMCPMC12775693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.